H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Dyadic International with a Buy rating and $3 price target. The company produces recombinant proteins based on proprietary fungus-based platforms, the analyst tells investors in a research note. The firm is "encouraged" by Dyadic's efforts to expand its platform into further non-pharmaceutical applications and views them as upside to estimates.
